Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis

Amyotrophic Lateral Sclerosis

Volumn 9, Issue 6, 2008, Pages 369-374

  Qureshi, Muddasir ^a,b   Shui, Amy ^a   Dibernardo, Allitia B ^a,b   Brown Jr , Robert H ^b   Schoenfeld, David A ^a   Cudkowicz, Merit E ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amyotrophic lateral sclerosis; Epidemiology; Inflammation; Motor neuron disease; Neuromuscular disease

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANTIDEPRESSANT AGENT; ASCORBIC ACID; BACLOFEN; BETA CAROTENE; BICARBONATE; CALCIUM; CELECOXIB; CHLORIDE; CREATINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; QUININE; RILUZOLE; TOPIRAMATE; UBIQUINONE;

ABNORMAL LABORATORY RESULT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BICARBONATE BLOOD LEVEL; CHLORIDE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; DRUG USE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; SURVIVAL TIME; VITAL CAPACITY;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ASPIRIN; FEMALE; FRUCTOSE; HUMANS; LABORATORY TECHNIQUES AND PROCEDURES; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 54049117205     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.1080/17482960802163614     Document Type: Article

References (31)

1. Armon, C. (2003) Epidemiology of amyotrophic lateral sclerosis/motor neuron disease. Motor Neuron Disorders, pp. 167-206. Butterworth Heinemann, Philadelphia
2. Traynor, B., Alexander, M., Corr, B., Frost, E. and Hardiman, O. (2003) An outcome study of riluzole in amyotrophic lateral sclerosis: A population-based study in Ireland, 1996-2000. J Neurol., 250, pp. 473-479.
3. Turner, M., Bakker, M., Sham, P., Shaw, C., Leigh, P. and Al-Chalabi, A. (2002) Prognostic modeling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord., 3, pp. 15-21.
4. Stambler, N., Charatan, M. and Cedarbaum, JM. (1998) Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology., 50, pp. 66-72.
5. Hadjikoutis, S. and Wiles, CM. (2001) Venous serum chloride and bicarbonate measurements in the evaluation of respiratory function in motor neuron disease. QJM., 94, pp. 491-495.
6. Cudkowicz, M., Shefner, J., Schoenfeld, D., Brown, RJ, Johnson, H. Qureshi, M. et al. (2003) A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology., 61, pp. 456-464.
7. Cudkowicz, M., Shefner, J., Schoenfeld, D., Zhang, H., Andreasson, K. Rothstein, J. et al. (2006) Trial of celecoxib in amyotrophic lateral sclerosis. Annals of Neurology., 60, pp. 22-31.
8. Shefner, JM, Cudkowicz, ME, Schoenfeld, D., Conrad, T., Taft, J. Chilton, M. et al. (2004) A clinical trial of creatine in amyotrophic lateral sclerosis. Neurology., 63, pp. 1656-1661.
9. Qureshi, M., Hayden, D., Urbinelli, L., Ferrante, K., Newhall, K. Myers, D. et al. (2006) Analysis of factors that modify susceptibility and rate of progression in amyotrophic lateral sclerosis (ALS). Amyotrophic Lateral Sclerosis., 7, pp. 173-182.
10. Cudkowicz, M., Qureshi, M. and Shefner, J. (2004) Measures and markers in amyotrophic lateral sclerosis. NeuroRx., 1, pp. 284-294.
11. Breslow, N. and Day, N. (1987) Statistical Methods in Cancer Research, Intl Agency for Research on Cancer, Lyon
12. Rothman, K. (1990) No adjustments are needed for multiple comparisons. Epidemiology., 1, pp. 43-46.
13. Szekely, C., Thorne, J., Zandi, P., Ek, M., Messias, E. Breitner, J. et al. (2004) Non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: A systematic review. Neuroepidemiology., 23, pp. 159-169.
14. McGeer, PL and McGeer, EG. (2007) NSAIDs and Alzheimer's disease: epidemiological, animal model and clinical studies. Neurobiology of Aging., 28, pp. 639-647.
15. Gordon, PH, Moore, DH, Miller, RG, Florence, JM, Verheijde, JL Doorish, C. et al. (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomized trial. Lancet Neurology., 6, pp. 1045-1053.
16. Popat, RA, Tanner, CM, Eeden, SK, Bernstein, AL, Bloch, DA Leimpeter, A. et al. (2007) Effect of non-steroidal anti-inflammatory medications on the risk of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis., 8, pp. 157-163.
17. Bilak, M., Wu, L., Wang, Q., Haughey, N., Conant, K. St Hillaire, C et al. (2004) PGE-2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Annals of Neurology., 56, pp. 240-248.
18. Zhao, W., Xie, W., Xiao, Q., Beers, D. and Appel, S. (2006) Protective effects of an anti-inflammatory cytokine, interleukin-4, on motor neuron toxicity induced by activated microglia. Journal of Neurochemistry., 99, pp. 1176-1187.
19. Shaheen, SO, Sterne, JAC, Songhurst, CE and Burney, PGJ. (2000) Frequent paracetamol use and asthma in adults. Thorax., 55, pp. 266-270.
20. Dimova, S., Hoet, PHM and Nemery, B. (2000) Paracetamol (acetaminophen) cytotoxicity in rat type II pneumocytes and alveolar macrophages in vitro. Biochemical Pharmacology., 59, pp. 1467-1475.
21. Yasui, M., Yoshida, M., Tamaki, T., Taniguchi, Y. and Ota, K. (1997) Similarities in calcium and magnesium metabolism between amyotrophic lateral sclerosis and calcification of the spinal cord in the Kii Peninsula ALS focus. Brain & Nerve., 49, pp. 745-751.
22. Oyanagi, K., Kawakami, E., Kikuchi-Horie, K., Ohara, K., Ogata, K. Takahama, S. et al. (2006) Magnesium deficiency over generations in rats with special references to the pathogenesis of the Parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam. Neuropathology., 26, pp. 115-128.
23. Oyanagi, K. (2005) The nature of the Parkinsonism-dementia complex and amyotrophic lateral sclerosis of Guam and magnesium deficiency. Parkinsonism & Related Disorders., 11, p. S17.
24. Lacomblez, L., Bensimon, G., Leigh, P., Guillet, P. and Meininger, V. (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet., 347, pp. 1425-1431.
25. Bensimon, G., Lacomblez, L. and Meininger, V. (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group. N Engl J Med., 330, pp. 585-591.
26. Miller, R., Mitchell, J., Lyon, M. and Moore, D. (2004) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
27. Edwards, I., Star, K. and Kiuru, A. (2007) Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf., 30, pp. 515-525.
28. Chong, P., Boskovich, A., Stevkovic, N. and Bartt, R. (2004) Statin-associated peripheral neuropathy: Review of the literature. Pharmacotherapy., 24, pp. 1194-1203.
29. Tsivgoulis, G., Spengos, K., Karandreas, N., Panas, M., Kladi, A. and Manta, P. (2006) Presymptomatic neuromuscular disorders disclosed following statin treatment. Arch Intern Med., 166, pp. 1519-1524.
30. Traynor, BJ, Zhang, H., Shefner, JM, Schoenfeld, D. and Cudkowicz, ME. (2004) Functional outcome measures as clinical trial endpoints in ALS. Neurology., 63, pp. 1933-1935.
31. Caroscio, J., Mulvihill, M., Sterling, R. and Abrams, B. (1987) Amyotrophic lateral sclerosis: Its natural history. Neurologic Clinics., 5, pp. 1-8.